Understand the source comparison
Hexarelin and Second-Generation GHRPs: Potency Versus Selectivity
Hexarelin represents the most potent growth hormone-releasing peptide in the GHRP class. Binding affinity studies show it activates GHS-R1a receptors approximately 20% more strongly than ipamorelin or GHRP-2. A 1998 study in the Journal of Endocrinological Inv
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Hexarelin represents the most potent growth hormone-releasing peptide in the GHRP class. Binding affinity studies show it activates GHS-R1a receptors approximately 20% more strongly than ipamorelin or GHRP-2. A 1998 study in the Journal of Endocrinological Investigation demonstrated that 2mcg/kg hexarelin produced GH peaks averaging 74ng/mL (compared to 28ng/mL for GHRP-6 at the same dose), with corresponding IGF-1 increases of 110% at week 8. The trade-off: hexarelin stimulates cortisol and prolactin release alongside growth hormone, which ipamorelin does not. This is why hexarelin is typically reserved for short-term protocols (8–12 weeks) rather than continuous use.
- The selectivity issue matters because chronic cortisol elevation impairs insulin sensitivity and can suppress thyroid function, both of which reduce hepatic IGF-1 production. Hexarelin's non-selective receptor activation also leads to faster desensitisation. Researchers using continuous hexarelin protocols report diminishing IGF-1 responses after 12–16 weeks, whereas ipamorelin and CJC-1295 combinations maintain efficacy beyond six months in published trials. Cycling strategies (4 weeks on, 2 weeks off) partially mitigate this, but the evidence base is weaker than for continuous lower-potency GHRP use.
- Research applications: hexarelin is most useful when rapid IGF-1 elevation is the primary goal and the protocol duration is defined upfront. Standard doses range from 100–200mcg administered 2–3 times daily. Hexarelin delivers the strongest acute GH response of any peptide secretagogue, but that potency comes with trade-offs that make it less suitable for long-term IGF-1 optimisation compared to ipamorelin or CJC-1295.